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Ancillary molecular testing has been recommended for thyroid fine-needle aspirates (FNA) with 
indeterminate cytologic diagnoses. Rosetta Genomics and Interpace Diagnostics have developed assays 
that can utilize direct smears as the testing substrate. 
METHODS: 
A retrospective study of indeterminate thyroid FNAs with known histologic follow-up was performed. 
One Diff-Quik-stained smear and one Papanicolaou-stained smear with similar cellularity (at least 60-100 
lesional cells) from each case were sent to Rosetta and Interpace, respectively, for analysis. The results 
were directly compared and correlated with the final histopathology. Neither company was aware of the 
follow-up histologic findings in these cases.  
RESULTS: 
A total of 10 thyroid FNAs were identified from our 2015 files. The cytologic diagnoses included 
follicular lesion of undetermined significance (FLUS, n=5), follicular neoplasm/suspicious for follicular 
neoplasm (FN/SFN, n=4), and suspicious for malignancy (SM, n=1). Of the seven cases with benign 
histology, 6 smears were classified as benign by the RosettaGXTM microRNA classifier, and 1 case was 
designated as suspicious. 5 cases were negative by both ThyGenXTM oncogene panel and ThyraMIRTM 
microRNA classifier. 1 case was negative by ThyGenX and positive on follow-up ThyraMIR, and 1 case 
was positive for KRAS mutation and positive on ThyraMIR. Both the RosettaGX and 
ThyGenX/ThyraMIR tests demonstrated positive results for the 3 histologically malignant cases.  
CONCLUSION: 
This study demonstrates that two molecular testing platforms performed equally well using our stained 
direct smears. Both molecular tests revealed a 100% negative predictive rate. RosettaGX showed a 75% 
positive predictive value (PPV) in comparison to 60% for ThyGenX/ThyraMIR.  
 




Thyroid cancer is the most common endocrine malignancy, and its incidence has steadily increased over 
the past few decades. It may present as a nodule palpated on physical exam or as an incidental finding on 
imaging.1-2 As with any mass or nodule detected, there is a fundamental level of uncertainty regarding its 
diagnosis and prognosis. Fine-needle aspiration (FNA) plays an important role in the initial evaluation of 
these patients.3 With its high sensitivity and specificity, it provides vital information for clinicians to 
formulate treatment plans and decide which patients might benefit from surgery.4 
  
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) recommends separation of FNAs 
into six main categories based on defined criteria. Each diagnostic group denotes a certain risk of 
malignancy.4-5 The majority of aspirates can diagnose thyroid nodules as benign or malignant.2,6-8 
However, a major limitation to thyroid FNA is the equivocal nature of numerous smears.7 The subjective 
aspect of interpretation and wide interobserver variability add additional levels of complexity.3-4,9 Up to 
30-40% of cases are borderline and classified as indeterminate.2,6,8-10 They are incorporated into the 
following groups: atypia of undetermined significance/follicular lesion of undetermined significance 
(AUS/FLUS, Bethesda category III); follicular neoplasm/suspicious for follicular neoplasm (FN/SFN, 
Bethesda category IV); and suspicious for malignancy (SM, Bethesda category V).5 
 
The study of molecular genetics in disease is a rapidly expanding field. Progress with research has 
identified genetic alterations associated with thyroid cancer.2,4,11 It has created opportunities to increase 
the diagnostic accuracy of thyroid FNA and redefine indeterminate aspirates for clinical management.4,12 
The importance of molecular markers was recently addressed in the 2015 American Thyroid Association 
(ATA) guidelines. Ancillary molecular testing has been recommended for thyroid fine-needle aspirates 
with indeterminate cytologic diagnoses.4,8-9,13 
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Many thyroid molecular tests employed by clinicians (Afirma and ThyroSeq) require that additional 
aspirates be procured and submitted in special collection media.4,6,14 Afirma Gene Expression Classifier 
(GEC) from Veracyte (South San Francisco, CA) uses microarray technology to assess the mRNA 
expression profile of indeterminate thyroid aspirates. It requires that personnel attain two dedicated FNA 
passes for evaluation with their proprietary algorithm. In comparison, ThyroSeq v2 (CBLPath, Rye 
Brook, NY) utilizes next-generation sequencing techniques to examine DNA mutations and RNA fusions. 
It has the particular requirement of needing 1-2 drops of aspirate material from the first pass of a thyroid 
FNA (Table 1).4,9 
 
However, two companies, Rosetta Genomics and Interpace Diagnostics, have developed microRNA-
based assays that can utilize direct smears as the testing substrate.1,6 Advancements with next-generation 
sequencing have allowed the discovery of novel targets for molecular testing, including microRNAs 
(miRNAs).10 MicroRNAs are small, noncoding RNA molecules that are intricately involved with 
regulating cellular function. They play a role in controlling the cell cycle with gene expression, 
proliferation, and survival.1,4,8,15 Numerous publications have reported the divergent expression of 
miRNAs in distinct tumors, including thyroid cancer.1,6,10,12,15 
 
Rosetta GX Reveal is a relatively new microRNA-based assay, and few articles have been published in 
the literature.1,6 This test evaluates the expression of 24 miRNAs, including not only ones upregulated in 
papillary thyroid carcinoma but also those that are downregulated. It has the unique feature of being 
developed for use with routinely prepared cytology smears (Table 1).1 The concept of extracting miRNAs 
from Papanicolaou or Romanowsky-stained slides is cutting edge for thyroid cytopathology.15  
 
Furthermore, Interpace Diagnostics introduced a multiplatform-testing algorithm to aid in the evaluation 
of indeterminate aspirates. ThyGenX is based on the oncogene panel originally marketed as miRInform 
by Asuragen.4,7 It maintains the same 4 DNA point mutations and 3 RNA translocation fusion markers 
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that are highly specific for differentiated thyroid cancer.10,12 It has been modified with next-generation 
sequencing and now can detect more than 100 genetic alterations across 8 genes (Table 1).4 Moreover, 
ThyraMIR is a molecular test designed to analyze the expression of 10 different microRNAs to further 
modify the risk of malignancy.4,8,10,15  
 
In the two-step process at Interpace, ThyGenX is performed first. If this oncogene panel is negative or 
only RAS mutations are identified, a reflex ThyraMIR test is then performed.9-10 With its initial release, 
ThyGenX and ThyraMIR required one additional FNA pass with at least 50 ng of cellular material 
submitted in a special preservative solution. Many recent review articles comparing the contemporary 
testing options available for thyroid aspirates perpetuate this factor.4,9 However, ThyGenX and ThyraMIR 
have been successfully performed on conventionally stained cytology smears, monolayer Thin Prep 
slides, and even formalin-fixed paraffin-embedded tissue through their internal validation process (Table 
1). Our study is the first to examine the feasibility of using the direct smears as the test samples.  
 
Utilizing direct smears for molecular testing is an exciting advancement in the field of thyroid cytology. 
With any FNA, there is a risk that the final interpretation may deviate from the rapid assessment. If 
nothing suspicious is appreciated at the on-site evaluation, cytologists may not request additional material 
up front. The ability to employ direct smears holds great promise for personalized medicine. Molecular 
assays can potentially be performed on prior cases in the archives to further aid treatment plans. It creates 




MATERIALS AND METHODS: 
This study was approved by the Institutional Review Board of Indiana University. A retrospective 
analysis of indeterminate thyroid FNAs with known histologic follow-up in 2015 was conducted at our 
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institution. A computer search of the cytopathology archives was performed to identify indeterminate 
aspirates with material collected for Afirma GEC testing and subsequent surgical intervention. All 
aspirates were categorized using the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). 
The cases had been evaluated by different board-certified cytopathologists and often presented at a 
consensus conference.  
 
We sought to evaluate the use of routinely stained cytology smears with two proprietary molecular testing 
platforms. Experienced cytotechnologists reviewed the cases to assess the level of cellularity on each 
smear. Rosetta accepts either air-dried Diff-Quik-stained or alcohol-fixed Papanicolaou-stained smears 
while Interpace only accepts Papanicolaou-stained smears. Therefore, one Diff-Quik-stained smear and 
one Papanicolaou-stained smear with similar cellularity (at least 60-100 lesional cells) were selected from 
each of 10 cases. The Diff-Quik-stained slide was sent to Rosetta Genomics (Rehovot, Israel), and the 
Papanicolaou-stained slide was submitted to Interpace Diagnostics (Parsippany, New Jersey) for 
molecular testing.  
 
The slides were stored and shipped at room temperature. Before performing the respective analyses, both 
Rosetta and Interpace take high-resolution images of the slides in their entirety. The whole slide images 
are archived and can be provided to the clients upon future request. The results were directly compared 
and correlated with the final histopathology. Neither company was aware of the follow-up histologic 




A total of 10 thyroid FNAs (7 females, 3 males; ages 25-65) were identified from our 2015 files. The 
cytologic diagnoses included follicular lesion of undetermined significance (FLUS, n=5), follicular 
neoplasm/suspicious for follicular neoplasm (FN/SFN, n=4), and suspicious for malignancy (SM, n=1). 
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All cases had material collected for Afirma GEC at the time of rapid assessment, and the test was 
performed in 7/10 of the samples (Table 2).  
 
Seven patients (7/10) had a total thyroidectomy, and three (3/10) underwent a lobectomy (Table 2). 
Investigating the circumstances surrounding the clinical decision to operate was beyond the scope of this 
study. The histologic results included nodular hyperplasia (n=1) and follicular adenoma (n=6). 
Malignancies comprised follicular variant of papillary thyroid carcinoma (FVPTC, n=1), papillary thyroid 
carcinoma (PTC, n=1), and follicular carcinoma (n=1) (Table 3). 
 
All 10 smears passed the preanalytical steps for quality assurance and were evaluated for microRNA 
(miRNA) expression with RosettaGX Reveal. Also, each case was interrogated for gene mutations and 
rearrangements with the oncogene panel ThyGenX. Only 9/10 of the cases were reflexed to the second 
tier of testing to detect miRNAs with ThyraMIR (Table 3). 
  
Of the seven cases with benign histology, 6 FNA smears were classified as benign by RosettaGX, and 1 
case was designated as suspicious. 5 cases were classified as negative by both ThyGenX and ThyraMIR. 
1 case was negative by ThyGenX and positive on follow-up ThyraMIR with a 50-60% risk of 
malignancy, and 1 case was positive for KRAS mutation and positive on ThyraMIR with a 50% risk of 
malignancy. In six of the benign cases, Afirma had been performed prior to our analysis. Only two were 
classified as benign while 4 of them were designated as suspicious (Table 3).  
 
Both the RosettaGX and ThyGenX/ThyraMIR tests demonstrated positive results for the 3 histologically 
malignant cases. Afirma GEC was performed in one malignant case and also demonstrated a suspicious 





Thyroid nodules are prevalent in the general population. Many are palpable on clinical exam while others 
are incidental findings on imaging. Fine-needle aspiration has proven to be a safe, minimally invasive, 
and cost-effective method for assessing these nodules. With each update in management guidelines 
published by the ATA, it continues to remain an integral part of the initial diagnostic evaluation.4 Most 
thyroid FNAs reliably identify samples as benign or malignant, and this can aid in directing treatment.6 
 
However, a compelling number are classified as indeterminate according to TBSRTC. The aggregate 
values range anywhere from 15-30% to 10-40% in the literature.1,6,9-10 The implied probability of 
malignancy within these indeterminate categories creates challenges for clinicians. According to 
TBSRTC, the risk of malignancy is 5-15% for AUS/FLUS (III), 15-30% for FN/SFN (IV), and 60-75% 
for SM (V).4-6 These numbers are too high to simply promote watchful waiting and follow-up.3-4,9 
 
Without clearer management guidelines, diagnostic lobectomy is a common surgical approach in 
treatment of patients with indeterminate diagnosis on FNA.9 The majority of these nodules, ranging from 
60-70%, prove to be benign on final histopathology, and surgical resection might be considered 
overtreatment.2,4,9-10 In contrast, those cases that prove malignant on lobectomy likely subject the patient 
to additional treatment. This might include a completion thyroidectomy or radioactive iodine ablation 
with subsequent risk of complications.2-3,9 
 
Improving the diagnostic yield from thyroid FNA is at the forefront of current research in 
cytopathology.2,12 Close analysis of nuclear detail and cytomorphologic characteristics will never 
completely eliminate the indeterminate category.3,7 Application of immunocytochemical stains also 
proved inadequate with low specificity and minimal reproducibility.4,7 As with many areas in medicine, 
the focus has shifted to molecular testing and detection of genetic alterations in thyroid cancer.2-4,12 The 
 9 
goal is to increase the number of malignancies accurately diagnosed on FNA and to reduce the extent of 
potentially avoidable surgeries.1,6-7,9-10 
 
The 2015 ATA management guidelines propose the use of molecular studies in indeterminate aspirates to 
enhance risk stratification and treatment planning.2,4,8,12-13 Much of the research surrounds identification of 
BRAF and RAS point mutations and RET/PTC and PAX8/PPARγ rearrangements.6,9,12,14 These four 
genes are well known to be the most common in differentiated thyroid cancer and have implications for 
diagnosis and prognosis.4,7,11 Nevertheless, there is a subset of tumors that lack these genetic aberrations.10 
 
Improvements in next-generation sequencing have substantially broadened the number of biomarkers that 
can be queried in a single thyroid aspirate.4,10,15 Since its commercial availability in 2011, Afirma GEC 
has made a significant impact on thyroid cytology. It uses a proprietary algorithm to analyze mRNA 
expression levels of 167 genes (Table 1).4,8 Its high negative predictive value and utility as a “rule out” 
test have been widely advertised among cytopathologists, endocrinologists, and surgeons.4,9-10 A 
drawback to the test is that it calls for two dedicated FNA passes. The decision to collect for Afirma GEC 
has to be made at the time of rapid assessment. Unless aspirates are immediately stored in preservative 
and shipped under specific conditions, the test cannot be performed.4,14 
 
Rosetta Genomics and Interpace Diagnostics are two companies that have recently developed microRNA-
based assays that can be successfully performed on direct smears. Preliminary data from the multicenter 
validation studies of Rosetta GX Reveal miRNA classifier are encouraging. The type of stain does not 
affect the assay, and it can be performed on smears that are stained with Papanicolaou, Diff-Quik, or 
Giemsa methods.1,6 Data collected from internal validation with ThyGenX/ThyraMIR (Interpace) also 
show good results, but the literature does not address their use with routinely prepared smears.4,6,14  
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The specifications from the manufacturers were naturally considered when designing our study. 
Preanalytic factors can never be completely excluded from having an impact on the data collection. In 
accordance with analytic validation studies, Rosetta Genomics allows submission of either Diff-Quik-
stained or Papanicolaou-stained slides. In contrast, Interpace can only accept Papanicolaou-stained 
smears. We sought to minimize the influence from preanalytic variables by carefully selecting slides of 
comparable cellularity from each case. One air-dried Diff-Quik-stained slide was shipped to Rosetta, and 
one Papanicolaou-stained smear was sent to Interpace.  
 
As with other molecular platforms, it is important to recognize that RosettaGX and ThyGenX/ThyraMIR 
are send-out tests. Diagnostic performance is one of many factors that will affect their utility with the 
advent of personalized medicine. Rosetta provides a rapid turnaround time of 7 days, and Interpace 
(ThyGenX/ThyraMIR) delivers a report within 10 to 14 days. Admittedly, conducting these assays will 
incur an extra cost for healthcare. Both companies work with patients, insurance plans, and various 
federal agencies to negotiate that aspect. The exact cost per test is likely dependent on many variables. A 
thorough examination may be of value in the future.  
 
This study demonstrates that these two molecular testing platforms performed equally well using our 
stained direct smears. Similar to Afirma GEC, the results from Rosetta are released as either benign or 
suspicious. RosettaGX had one false positive in our sample population. The smear was flagged as 
suspicious, and it was associated with a follicular adenoma on subsequent thyroidectomy.  
 
In contrast, Interpace uses a two-step algorithm for testing and takes a different approach with their 
results. If ThyGenX oncogene panel is positive, it characterizes the mutation and assigns an associated 
risk of malignancy. When ThyGenX is negative or only RAS mutations are identified, reflex ThyraMIR is 
performed. The risk of malignancy is subsequently modified based on the microRNA expression.9-10 The 
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established system does not separate samples into clearcut benign or malignant categories. It was 
developed to provide additional data for the clinical team to formulate treatment plans.  
 
As with many ancillary tests, the results should be considered along with patient history, presenting 
symptoms, and imaging characteristics. Risk assessment does not directly conform to traditional 
calculations of sensitivity and specificity. To foster some statistical analysis of our results, we used the 
interpretation of 50% or higher risk of malignancy as the cutoff for a positive test. ThyGenX/ThyraMIR 
resulted in two false positives, and both correlated with follicular adenomas on resection. One was 
negative on ThyGenX and positive on reflex ThyraMIR with an estimated 50-60% risk of malignancy. 
The second case was positive for KRAS mutation (ThyGenX) and ThyraMIR with a projected risk of 
50% (Table 3). 
 
When assessing risk of malignancy, it is evident that our results are based on a low number of cases, and 
this may bias the figures. We acknowledge this as a potential limitation, but we hope our findings can 
spark interest for future investigation. Both RosettaGX and ThyGenX/ThyraMIR demonstrated a 
sensitivity of 100%. This is along the same trajectory as the data described in the literature with a 
sensitivity of 85% for RosettaGX and 89% for ThyGenX/ThyraMIR.1,4,9-10 In our analysis, RosettaGX 
demonstrated a specificity of 86%, which is higher than the industry reported value of 72%.1 In 
comparison, ThyGenX/ThyraMIR showed a specificity of 71%, which is slightly lower than the published 
value of 85% (Table 4).4,9-10 
 
Both molecular tests revealed a 100% negative predictive rate. RosettaGX showed a 75% positive 
predictive value (PPV) in comparison to 60% for ThyGenX/ThyraMIR (Table 4). The data is undoubtedly 
affected by our small sample size, but it shows promising results. Utilizing stained direct smears is a new 
and innovative approach to molecular analysis in thyroid cytology. A long-term analysis with RosettaGX 
and multiplatform ThyGenX/ThyraMIR on a larger sample size is needed to reinforce the strength of 
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these assays with direct smears. Even if additional material is not requested during the on-site evaluation, 
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